Oslo, 26 November 2024, the CEO of Lytix Biopharma, Dr. Øystein Rekdal, today gave a company presentation at the DNB Nordic Healthcare conference. In its presentation, Lytix Biopharma presented updated results from its study in patients with the skin cancer disease basal cell carcinoma, with its licensing partner Verrica Pharmaceuticals (preliminary results announced medio August). The study investigates Lytix’s lead drug candidate LTX-315 in BCC patients and shows impressively an:
• 97 percent overall response rate (ORR)
Additional efficacy data, previously reported in August 2024 shows 86 percent overall reduction of tumor size, in addition to 51 percent complete clearance rate of basal cell carcinomas (total removal).
Lytix has significantly reduced its development risk, based on positive phase II results and progress towards a potential phase III study. Basal cell carcinoma is the largest skin cancer disease globally with a projected global market size of USD 11.5 bn in 2028 (CAGR 7.9%) and 3.6 million new cases in the US annually.
Please find the presentation attached.
For any questions, please contact:
Gjest Breistein, CFO
gjest.breistein@lytixbiopharma.com
+47 952 60 512
About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.